Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: Rob_StCloudFL who wrote (31093)	6/23/2015 8:28:30 PM
From: stockdoc77	1 Recommendation Recommended By slimchance Read Replies (1) \| Respond to of 63283

You rarely post but you make sense to me. I still think I am protected from extreme downside risk by 132, which I feel is a very good asset and will get a partner this year. I personally expect a deal for more than 100 million dollars, but I confess to irrationial exuberance. I had a significant margin position which I liquidated last week, can't take that kind of risk, but still own plenty of shares. As Idaho has stated many times, all the data on Emab in SLE has been strongly positive going back to the original P2 with 14 patients in 2005. I give us a better than 50% chance of success. We should know shortly. The second trial finished enrolling last June I believe and the final patients need to finish 48 weeks. Data crunching etc takes some time, but headline results should not take much longer.